NewLink Genetics Corporation logo
Source: Lumos Pharma, Inc.

NewLink Genetics to Participate in the Baird Global Healthcare Conference

AMES, Iowa, Aug. 21, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that the company will present at the 2018 Baird Global Healthcare Conference on Wednesday, September 5, 2018, at 11:25AM ET. 

A live webcast of the presentation will be available on the Company’s website at www.newlinkgenetics.com in the “Investors & Media” section under “Events and Presentations.”  An archived edition of the presentation will be available on the Company’s website later that day. 

About NewLink Genetics Corporation

NewLink Genetics is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer. NewLink Genetics' leading drug candidate, indoximod, is an investigational, orally available small molecule designed to harness multiple components of the immune system to combat cancer. For more information, please visit www.newlinkgenetics.com and follow us on Twitter @NLNKGenetics.

Investor Contact:

Lisa Miller
Director of Investor Relations
NewLink Genetics
515-598-2555
lmiller@linkp.com

Media Contact:

Sharon Correia
VP, Integrated Communications
LaVoieHealthScience
617-374-8800, ext. 105
scorreia@lavoiehealthscience.com